Chris ViehbacherHealth Canada Approves Leqembi for Early Alzheimer's Treatment100% left coverage1 source
Chris ViehbacherHealth Canada Approves Leqembi for Early Alzheimer's Treatment100% left coverage1 source
Chris ViehbacherLeqembi Slows Alzheimer's Progression 34% Over Four Years100% right coverage2 sources
Chris ViehbacherLeqembi Slows Alzheimer's Progression 34% Over Four Years100% right coverage2 sources
Chris ViehbacherBiogen plans to consolidate headquarters in MIT Kendall Common by 2028100% left coverage1 source
Chris ViehbacherBiogen plans to consolidate headquarters in MIT Kendall Common by 2028100% left coverage1 source